Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Multi-center Phase III Clinical Trial to Investigate the Safety and Efficacy Between YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia

Next Previous
X
Search
Trial Profile

A Double-blind, Randomized, Multi-center Phase III Clinical Trial to Investigate the Safety and Efficacy Between YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosuvastatin/telmisartan (Primary) ; Rosuvastatin; Telmisartan
  • Indications Essential hypertension; Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Yuhan

    • Most Recent Events

    • 16 Apr 2018 Primary endpoint (Percent change in LDL-C [FDC and rosuvastatin groups]) has not been met, according to the results published in the Clinical Therapeutics.
    • 16 Apr 2018 Primary endpoint has been met. (Percent change in LDL-C [FDC group and the telmisartan group])
    • 16 Apr 2018 Primary endpoint has not been met. (Change in mean sitting diastolic blood pressure (MSDBP) [FDC group and the telmisartan group])

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top